Study of Albumin to Reduce Inflammation Following Surgery
Information source: Imperial College London
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Systemic Inflammatory Response Syndrome; Cardiopulmonary Bypass
Intervention: 20% Human albumin solution (Drug); Gelofusin (Drug)
Phase: Phase 2
Status: Terminated
Sponsored by: Imperial College London Official(s) and/or principal investigator(s): Mark J Griffiths, Principal Investigator, Affiliation: Royal Brompton & Harefield NHS Foundation Trust
Summary
The purpose of this study is to determine whether albumin administration during cardiac
surgery is effective in attenuating the development of inflammation following surgery.
Clinical Details
Official title: Scavenging Free Haemoglobin Attenuates the Systemic Inflammatory Response Following Surgery
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Time from surgery to intensive care unit discharge
Secondary outcome: Degree of hemolysis - free hemoglobin and haptoglobinHaematological and physiological markers of the inflammatory response - Temperature, pulse rate, respiratory rate, white cell count and C-reactive protein Biochemical and physiological markers of organ dysfunction Haematological markers of the inflammatory response
Detailed description:
The host response to infection and other forms of tissue injury has been termed the systemic
inflammatory response syndrome (SIRS). SIRS is seen in association with a wide variety of
non-infective insults, including major trauma and surgical procedures, including those
necessitating cardiopulmonary bypass (CPB). In this population the incidence of SIRS is
high, afflicting up to 70% of patients. This may be manifest from an increased vasopressor
requirement, to refractory hypotension, and multiple organ dysfunction syndrome (MODS) with
liver, renal, myocardial, and neurological problems. MODS is associated with significant
mortality rates of around 30-45%. Survivors require prolonged and costly intensive care,
thereby representing a considerable burden for the healthcare services. Survivors often
suffer considerable morbidity and have significantly impaired health related quality of
life.
Despite intense investigations of anti-inflammatory therapies in SIRS and its sequelae, the
case of patients is largely supportive whilst underlying triggers (such as infection) for
the process are treated. Indeed, the only therapy drotrecogin alfa (activated) demonstrated
to reduced mortality in a randomised study has only been investigated in patients with the
most severe SIRS consequent of infection (i. e. severe sepsis) and is contra-indicated in
those who have just undergone surgery.
Haemolysis is a common feature of surgery requiring CPB and may potentiate the development
of SIRS and organ injury through the release of heme/iron. Furthermore, haemolysis during
CPB may lead to the depletion of important mechanisms which scavenge free heme/hemoglobin
from the circulation. Albumin, the most abundant plasma protein, has specific and
non-specific heme and iron binding sites which are used under circumstances in which
standard scavengers are overwhelmed. However, albumin is also depleted following CPB. It is
therefore hypothesised that by priming the CPB circuit with albumin the heme/iron scavenging
capability of the plasma will be maintained following surgery and that the systemic
inflammatory response will be attenuated.
Eligibility
Minimum age: 16 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- All patients over sixteen years of age undergoing surgery that requires
cardiopulmonary bypass who provide informed written consent
Exclusion Criteria:
- Lack of informed consent
- Pregnancy
- Cyanotic congenital heart disease (due to high haemoglobin levels and increased
haemolysis)
- Patients undergoing other extracorporeal interventions (ventricular assist devices,
extracorporeal membrane oxygenators, pre-admission dialysis)
- Patients with congenital haemoglobinopathies (e. g. thalassaemia, cryoglobinuria, etc)
- Patients with disorders of iron metabolism (e. g. haemochromatosis)
- Religious objections to transfusion of a plasma-derived product
- Patients with known blood borne infection
- Patients with known hypersensitivity to gelofusine or human albumin solution
- Patients with an additive EUROSCORE of 10 or more
Locations and Contacts
Adult Intensive Care Unit, Royal Brompton and Harefield NHS Trust, London SW3 6NP, United Kingdom
Additional Information
Starting date: December 2008
Last updated: May 27, 2014
|